InVivo Therapeutics Holdings Corp. [NASDAQ: NVIV] closed the trading session at $1.09 on 03/05/21. The day’s price range saw the stock hit a low of $0.90, while the highest price level was $1.12. The company report on March 5, 2021 that InVivo Therapeutics Announces Presentation at Upcoming 2021 H.C. Wainwright Global Life Sciences Conference.
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming 2021 H.C. Wainwright Global Life Sciences Conference. The conference is scheduled to be held March 9-10, 2021 in a virtual format. Dr. Toselli’s presentation will provide an overview of the company and highlight key business updates for the company.
A webcast of the presentation will be available on the Investor Relations – Events section of the InVivo website at https://investors.invivotherapeutics.com/events beginning March 9, 2021 at 7:00 am ET. In addition to the company’s presentation, Dr. Toselli and company management will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
The stocks have a year to date performance of 34.57 percent and weekly performance of -5.22 percent. The stock has been moved at -15.50 percent over the last six months. The stock has performed -16.15 percent around the most recent 30 days and changed 55.71 percent over the most recent 3-months.
If compared to the average trading volume of 5.74M shares, NVIV reached to a volume of 4814049 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about InVivo Therapeutics Holdings Corp. [NVIV]:
Raymond James have made an estimate for InVivo Therapeutics Holdings Corp. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on July 31, 2017. The new note on the price target was released on May 05, 2017, representing the official price target for InVivo Therapeutics Holdings Corp. stock.
The Average True Range (ATR) for InVivo Therapeutics Holdings Corp. is set at 0.19 The Price to Book ratio for the last quarter was 0.98, with the Price to Cash per share for the same quarter was set at 0.69.
NVIV stock trade performance evaluation
InVivo Therapeutics Holdings Corp. [NVIV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.22. With this latest performance, NVIV shares dropped by -16.15% in over the last four-week period, additionally sinking by -15.50% over the last 6 months – not to mention a drop of -77.75% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVIV stock in for the last two-week period is set at 43.41, with the RSI for the last a single of trading hit 40.60, and the three-weeks RSI is set at 46.15 for InVivo Therapeutics Holdings Corp. [NVIV]. The present Moving Average for the last 50 days of trading for this stock 1.1765, while it was recorded at 1.0812 for the last single week of trading, and 1.2310 for the last 200 days.
InVivo Therapeutics Holdings Corp. [NVIV]: An insightful look at the core fundamentals
Return on Total Capital for NVIV is now -67.13, given the latest momentum, and Return on Invested Capital for the company is -68.53. Return on Equity for this stock declined to -73.27, with Return on Assets sitting at -58.10. When it comes to the capital structure of this company, InVivo Therapeutics Holdings Corp. [NVIV] has a Total Debt to Total Equity ratio set at 5.32. Additionally, NVIV Total Debt to Total Capital is recorded at 5.05, with Total Debt to Total Assets ending up at 4.66. Long-Term Debt to Equity for the company is recorded at 3.61, with the Long-Term Debt to Total Capital now at 3.43.
Reflecting on the efficiency of the workforce at the company, InVivo Therapeutics Holdings Corp. [NVIV] managed to generate an average of -$1,512,333 per employee.InVivo Therapeutics Holdings Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.00 and a Current Ratio set at 10.00.
Earnings per share (EPS) analysis for InVivo Therapeutics Holdings Corp. [NVIV] stock
With the latest financial reports released by the company, InVivo Therapeutics Holdings Corp. posted -8.4/share EPS, while the average EPS was predicted by analysts to be reported at -8.7/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 3.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVIV.
InVivo Therapeutics Holdings Corp. [NVIV]: Insider Ownership positions
There are presently around $0 million, or 6.90% of NVIV stock, in the hands of institutional investors. The top three institutional holders of NVIV stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 111,474, which is approximately New of the company’s market cap and around 12.35% of the total institutional ownership; TWO SIGMA ADVISERS, LP, holding 59,100 shares of the stock with an approximate value of $64000.0 in NVIV stocks shares; and TOWER RESEARCH CAPITAL LLC (TRC), currently with $50000.0 in NVIV stock with ownership of nearly New of the company’s market capitalization.
Positions in InVivo Therapeutics Holdings Corp. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 6 institutional holders increased their position in InVivo Therapeutics Holdings Corp. [NASDAQ:NVIV] by around 267,777 shares. Additionally, 6 investors decreased positions by around 87,823 shares, while 7 investors held positions by with 74,108 shares. The mentioned changes placed institutional holdings at 281,492 shares, according to the latest SEC report filing. NVIV stock had 4 new institutional investments in for a total of 260,422 shares, while 3 institutional investors sold positions of 81,494 shares during the same period.